Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 15, 2021

Primary Completion Date

June 15, 2023

Study Completion Date

December 31, 2025

Conditions

Multiple Sclerosis

Interventions

DRUG

tolebrutinib 60mg

60 mg orally

DRUG

tolebrutinib 120mg

120 mg orally

Trial Locations (1)

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH